




NanoViricides
Incorporated

“Find-Encapsulate-Destroy”

Nanotechnology-enabled,
Targeted,
Virus-Killing Treatments

**Novel Mechanism Ensuring Expanding Pipeline
of First-In-Class Drug Candidates**



NanoViricides : Mimicking Cells, Fooling Viruses!

Advanced Pre-clinical Leads

Influenzas
Epidemic H1N1
“Swine Flu”
Seasonal Influenzas
H7N, H9N, High Path
Avian Influenzas
H5N1 Bird Flu

* **FluCide™**
one Drug for All

**EKC Causing
Adenovirus**

* **Eye Drops**
against Most
Front Eye Viruses

Herpes
Oral & Genital
 (“Cold Sores”)

* **Skin Cream for**
Oral, Genital
Cold Sores

HIV

* **HIVCide™**
“Functional
Cure” ?

**Dengue Viruses,
West Nile Virus,
Yellow Fever Virus,
Jap. Encephalitis
Virus**

* **Denguecide**
Avoid ADE Effect



NanoViricides

Incorporated

“Find-Encapsulate-Destroy”

Nanotechnology-enabled,
Targeted,
Virus-Killing Treatments

DRUG PIPELINE

HIV-CIDE™

Anti-HIV nanoviricide showed efficacy superior to HAART cocktail in animal studies.

EKC-CIDE™

Topical solution for most front eye diseases caused by viruses

FLU-CIDE™

For Seasonal Influenzas, Bird Flu, Epidemic Flu, “Swine Flu”

Excellent efficacy shown in H1N1-animals, H5N1 in vitro.

HERPECID™

Skin Cream for Oral and Genital Herpes Virus Infections

DENGUECIDE™

Broad-Spectrum Treatment for all 4 types of Dengue Viruses

MORE IN R&D

FEATURES

 **OVERCOME RESISTANCE FROM VIRUS MUTATION**

 **BEYOND ANTIBODIES AND VACCINES**

STAGE

 **ADVANCED PRECLINICAL DRUG CANDIDATES**

TECHNOLOGY

 **BIOMIMETIC VIRUS TRAPPING**

★ **SPECIFIC VIRUSES**
eg. for Influenza, HIV

★ **BROAD-SPECTRUM**
i.e. attacking many kinds of viruses with a single drug

 **“ACCURATE-DRUG-IN-FIELD” (ADIF™) FOR BIODEFENSE**

Company Overview

NanoViricides, Inc. is a development stage company with a unique nanomedicine technology. The Company is developing nanotechnology-based biomimetic anti-viral medicines, that we call “nanoviricides®”. Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. HIV, seasonal and potentially-epidemic influenzas and bird flu, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness.

Unique Find-Encapsulate-Destroy Antiviral Strategy

A “nanoviricide” is an agent designed by the Company to fool a virus into attaching to this agent, in the same way that the virus normally attaches to receptors on a cell surface. Once attached, the flexible nanoviricide glob wraps around the virus and traps it. In the process, the virus also loses its coat proteins that it needs to bind to a cell. The virus is thus neutralized and effectively destroyed. Nanoviricides complete the task of dismantling the virus particle without immune system assistance. Thus nanoviricides represent the next great advance in “Immunotherapeutics” or antibodies and vaccines, the well established antiviral strategies.

Viruses have developed smart strategies to derail the human immune system function.

Versatile Technology

A nanoviricide is created by chemically attaching a virus-binding ligand, derived from the binding site of the virus located on cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a virus mutates.

Virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands.

Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg. *This is similar to antibiotics such as penicillin against bacteria that exploit a feature common to all bacteria.*

Our ADIF Technology enables the creation of a virus-specific accurate drug in the field. This is the only way to effectively respond to novel and emerging infectious diseases and bioterrorism agents rapidly. We have successfully demonstrated this technology.

Strong Nanomedicines Intellectual Property Portfolio

NanoViricides, Inc. product candidates are based on TheraCour® technology invented and developed by company president and founder Anil R. Diwan, PhD. NanoViricides, Inc. holds an exclusive, worldwide license to this technology for its antiviral drugs. The technology is protected by two very broad international patent applications that cover compositions of matter, processes of manufacture, methods of use, and fields of use. Additional patent applications are expected, and the Company intends to patent each drug separately as well.

Independent Researchers Perform Biological Testing

The Company has several collaborations at leading academic and federal institutions. Their independent researchers perform nanoviricides testing against various viral targets. The core intellectual property sensitive activities are performed by us. This drug development strategy saves on capital needs and provides unbiased data on our drug candidates.

Robust Drug Commercialization & Marketing Strategy

The Company strategy is focused on achieving FDA approvals and commercialization of nanoviricides drugs to maximize investor returns as well as provide social benefit. **Pharmaceutical Company Collaborations** will be sought for the commercially important drug candidates including EKC-Cide, HIV-Cide, Flu-Cide, anti-HSV drug, and later, a drug against Hepatitis C, among others. Our **Social Responsibility Programs** include neglected tropical diseases (NTDs) such as Dengue, Infant Diarrhea (rotavirus), Rabies, and others. In addition, we anticipate our **BioSecurity Programs** which include the ADIF technology, and broad-spectrum nanoviricides against viral hemorrhagic fevers (VHFs) including Ebola/Marburg, to be developed with government collaborations and funding.

Strong Leadership and Management Team

Eugene Seymour, MD, MPH, Chief Executive Officer, has been working in the HIV field since the very first AIDS cohort was identified. This is his second public company.

Anil R. Diwan, PhD, President and Chairman, has invented and developed novel nanomedicine technologies. He holds a PhD from Rice University, TX, and a B.Tech. from IIT-Bombay, India. He has 20+ years of experience running entrepreneurial businesses and R&D.

Randall W. Barton, PhD, Chief Scientific Officer, has over 20 years of experience in drug discovery and early stage drug development of both small molecules and biologicals in immunology, virology and cardiovascular diseases at Boehringer Ingelheim Pharmaceuticals. He has over 70 scientific publications, 5 patents, and 3 patent applications. Dr. Barton has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory.

Krishna Menon, VMD, PhD, MRCS, Chief Regulatory Officer-Consulting, was most recently Group Leader, Cancer In-Vivo Research and Clinical Development, at Eli Lilly. He has led the development of several blockbuster drugs. He has a PhD in Pharmacology from Harvard and was a research scientist at Dana Farber Institute.

Jayant Tatake, PhD, Vice-President of R&D, is a co-inventor of the Company's nanomedicine technologies. Dr. Tatake has over 23 years experience with pharmaceutical production from lab scale through c-GMP manufacture. He holds a PhD from UICT-Bombay.

Renowned Scientific Advisory Board (SAB)

The Company's Scientific Advisory Board consists of highly renowned scientists. **Prof. Paul Marks, our SAB Chairman**, Rockefeller Institute & President-Emeritus, Memorial Sloan-Kettering Cancer Center; **Prof. Cy Stein**, Head, Medical Genitourinary Oncology, Albert Einstein College of Medicine; **Prof. John Rossi**, Dean, City of Hope Beckman School of Graduate Studies; **Dr. Howard Fields**, retd. Chief, Molec. & Immunodiagnostics Section, Hepatitis Branch, CDC; **Dr. Harmon Aronson**, a renowned pharmaceutical industry consultant; **Prof. Kazuo Tsubota**, Chairman, Ophthalmology Dept., Keio University School of Medicine, Japan; and **Prof. Thomas Lentz**, Emeritus Professor and a pioneer in virus-directed bio-mimetic therapeutics, Yale University; advise us.

Extremely Effective (Pre-Clinical) Treatments

FluCide™, our anti-influenza drug candidate, was shown to be more than 15X (1,500%) more effective than extended treatment with Tamiflu®, (Roche), in a lethal animal model.

HIVCide™, our anti-HIV drug candidate demonstrated effectiveness equal to a three drug cocktail (HAART) even with less than 12X reduced dosages in the SCID-huThy/Liv mouse model. If the results hold in humans, it could be a potential "Functional Cure" for HIV/AIDS.

EKC-Cide™, our antiviral eye drops demonstrated complete clearance of adenoviral epidemic kerato-conjunctivitis (EKC) within 2.5 days in a rabbit model.

HerpeCide™, our skin cream against oral and genital herpes, has shown near-complete inhibition of two different HSV-1 strains, viz McKrae, important for eye infections, and H129, a highly pathogenic, encephalitic strain important for oral and genital herpes.

DengueCide™, our broad-spectrum drug candidate against all four types of dengue, has led to survival of 50% of mice in an ADE (antibody-dependent-enhancement) model of dengue infection, clinically relevant for the high fatality rate dengue manifestations.

Large Market Size - over \$40B total by 2013 (1)

Viral Disease	Mkt Size 2013	NNVC Opportunity
HIV/AIDS	\$ 21 Billion (B)	HIV-Cide a "Functional Cure"?
Influenza, Bird Flu	\$ 7 B	Resistance to current drugs widespread
Viral Diseases of Ext. Eye	\$ 1 B	No current non-toxic drugs ⁽²⁾
Hepatitis C	\$ 6 B	Current therapies not very effective
Herpes-Cold Sores, Genital	\$ 2 B	
Dengue, Rabies, other	\$ 1 B(combined)	Rapidly increasing Developing World markets ⁽²⁾
Ebola/Marburg/VHF	\$ 1 B(combined)	Biodefense, Biosecurity ⁽²⁾

(1). Jain Pharma Biotech. March 2009. "Antiviral Therapeutics: Technologies, Companies & Markets", by Prof. K. K. Jain, MD, FRACS, FPPM. Basel, Switzerland. (2). Estimates based on the Jain Report, and a report commissioned by the Company for more detailed analyses of these special markets. March 2009.

Disclosure Statement

This disclosure document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The forward-looking statements are based on current expectations, estimates and projections made by management. The Company intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Important factors that could cause actual results to differ materially from the Company's expectations include, but are not limited to, those factors that are disclosed from time to time with the United States Securities and Exchange Commission.

LEADERSHIP

Chairman and President:

ANIL R. DIWAN, PHD

Chief Executive Officer:

EUGENE SEYMOUR, MD MPH

Chief Scientific Officer:

RANDALL W. BARTON, PHD

Chief Regulatory Officer:

KRISHNA MENON, VMD, PHD

Vice-President, R&D:

JAYANT G. TATAKE, PHD

CORPORATE INFO

Founded: 2005.

OTC-BB Symbol: NNVC

Public Since: June, 2005

Shares Outstanding as of Dec. 2010: approximately 139M.

CONTACT

Corporate

Email: Info@nanoviricides.com

Tel/Fax : (203)-937-6137

Mailing Address:

NanoViricides, Inc.
135 Wood Street, Ste. 205
West Haven, CT 06516.

Investors; Media;

Business Development

EUGENE SEYMOUR, MD, MPH, CEO.

eugene@nanoviricides.com

R&D; Collaborations

RANDALL W. BARTON, PHD, CSO.

rwbbarton@nanoviricides.com


Website

www.nanoviricides.com

Nanoviricides Are Highly Effective and Safe


FluGide™ is Unquestionably Superior to Tamiflu®

Significant Increase in Life Span upon Treatment
H1N1 Mice Lethality Study



FluGide Could Be The Most Effective Anti-Influenza Drug Candidate At Present

Nanoviricides Dismantling MCMV Virus Particle



Nanoviricide Treatment was >12X more effective than the HAART standard therapy in a SCID-hu Thy/Liv Mouse Model

- * Only 300mg/kg total HIVCide produced effect equal or better than 4,100 mg/kg HAART drugs load
- * Viral Load Reduction on nanoviricides treatment was equal to or better than that on HAART treated mice
- * CD4+/CD8+ (human) T cells increased equal to or better than that on HAART treated mice
- * Virus particle count inside human T cells decreased to much smaller levels on nanoviricide treatment compared to HAART treatment

Potential "Functional Cure" for HIV/AIDS?

Significant Survival of Mice in Dengue Virus Lethal Infection ADE Model

- * First Ever Significant Survival Other than for Specific MABs
- * **Broad-Spectrum Nanoviricide:** Drug May Work Against All Dengue Virus Types and possibly related Flaviviruses
- ADE = Antibody-Dependent Enhancement of Dengue Virus Infection. Causes Severe Dengue, Dengue Hemorrhagic Fever, with high fatality rates.

Different HSV-1 Viruses Completely Inhibited in Several Different Cell Culture Studies

- * >99.99% Reduction of HSV-1 McKrae Strain
- * McKrae Strain important in Herpes Keratitis (External Eye)
- * **Almost Complete Inhibition of HSV-1 H129 Strain**
- * H129: relevant for "Cold Sores", a Highly Pathogenic Strain

Eye Drops - Broad-Spectrum Nanoviricide

